Table 3:
Treatment of the Oldest Glioblastoma Patients
| N (%) | |
|---|---|
| Surgerya | |
| Biopsy | 45 (45) |
| Subtotal resection | 30 (30) |
| Gross resection | 25 (25) |
| First-line treatmentb | |
| TMZ | 14 (14) |
| RT | 35 (36) |
| RT/ TMZ | 10 (10) |
| RT/TMZ → TMZ | 2 (2) |
| Trial (RT/ Bev)c | 1 (1) |
| Bev | 1 (1) |
| None | 34 (35) |
| Patient’s wish | 10 (10) |
| Reduced overall condition | 19 (20) |
| Second-line treatmentb | |
| Surgery at recurrence | 2 (2) |
| Surgery alone | 1 (1) |
| Surgery + Alkyl | 1 (1) |
| Bev | 2 (2) |
| Bev + Alkyl | 2 (2) |
| TMZ | 6 (6) |
| RT | 2 (2) |
| Third-line treatmentb | |
| Bev | 4 (4) |
| Bev + rindopepimut | 1 (1) |
| Lomustine | 1 (1) |
Abbreviations: Alkyl, alkylating antineoplastic agent; Bev, bevacizumab; EOR, extent of resection; RT, radiotherapy; RT/TMZ, radiotherapy with concomitant temozolomide; RT/ TMZ → TMZ, radiotherapy with concomitant temozolomide, followed by maintenance treatment with temozolomide; RT/ Bev, radiotherapy with concomitant bevacizumab; TMZ, temozolomide.
aData available for 100 patients.
bData available for 97 patients.
cARTE trial, RT + bevacizumab.